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Abstract
Background: Dengue is a mosquito-borne viral disease caused by four closely related serotypes of Dengue viruses (DENVs).
This disease whose symptoms range from mild fever to potentially fatal haemorrhagic fever and hypovolemic shock,
threatens nearly half the global population. There is neither a preventive vaccine nor an effective antiviral therapy against
dengue disease. The difference between severe and mild disease appears to be dependent on the viral load. Early diagnosis
may enable timely therapeutic intervention to blunt disease severity by reducing the viral load. Harnessing the therapeutic
potential of RNA interference (RNAi) to attenuate DENV replication may offer one approach to dengue therapy.
Methodology/Principal Findings: We screened the non-translated regions (NTRs) of the RNA genomes of representative
members of the four DENV serotypes for putative siRNA targets mapping to known transcription/translation regulatory
elements. We identified a target site in the 59 NTR that maps to the 59 upstream AUG region, a highly conserved cis-acting
element essential for viral replication. We used a replication-defective human adenovirus type 5 (AdV5) vector to deliver a
short-hairpin RNA (shRNA) targeting this site into cells. We show that this shRNA matures to the cognate siRNA and is able
to inhibit effectively antigen secretion, viral RNA replication and infectious virus production by all four DENV serotypes.
Conclusion/Significance: The data demonstrate the feasibility of using AdV5-mediated delivery of shRNAs targeting
conserved sites in the viral genome to achieve inhibition of all four DENV serotypes. This paves the way towards exploration
of RNAi as a possible therapeutic strategy to curtail DENV infection.
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Introduction
The genus Flavivirus, of the family Flaviviridae, includes several
vector-borne viruses of which the four serotypes of dengue viruses
(DENV-1, -2, -3 and -4) have emerged as the most significant of
current challenges to global public health [1,2]. The DENVs have
single-stranded ,11 kilobase (kb) long 59capped RNA genomes of
positive polarity, containing a single open reading frame (ORF),
flanked by ,100 nucleotide (nt) 59 and ,450 nt 39 non-translated
regions (NTRs) [3]. Upon infection of susceptible cells by DENV,
the ORF is translated into a single ,3400 amino acid (aa) residue
polyprotein precursor which matures into 3 structural proteins, the
capsid, envelope and membrane, and 7 non-structural (NS)
proteins, NS1, 2a, 2b, 3, 4a, 4b and 5. This is followed by
replication, mediated principally by NS3 and NS5, of the sense
genomic RNA through a complementary antisense RNA inter-
mediate [3]. Infection with any of the four DENVs can cause mild
and often self-limiting dengue fever (DF) or severe, potentially fatal
dengue haemorrhagic fever (DHF) and dengue shock syndrome
(DSS) [4]. The severe manifestations of dengue disease, which are
more common in hyper-endemic areas during secondary infection
with a heterologous DENV serotype, have been correlated to high
levels of viremia [5,6]. Dengue disease which is spread to humans
by mosquitoes, threatens almost half the global population. The
World Health Organization estimates indicate that globally there
are ,50 million DENV infections each year, with ,500,000 of
these resulting in DHF/DSS, claiming ,12,500 lives [4]. Though
promising live attenuated dengue vaccine candidates are currently
in clinical trials, the complex role of the immune system in dengue
pathogenesis and viral interference among the four serotypes
continue to pose challenging hurdles [1,2]. Further, no antiviral
therapy is currently available to treat DENV infections.
From the perspective of antiviral therapy, the discovery of gene
silencing by RNA interference (RNAi) has provided a novel tool.
RNAi, first identified to serve an antiviral defence role in plants
and insects [7] is an evolutionarily conserved phenomenon that
utilizes multiple mechanisms to control eukaryotic gene expression
and function through sequence complementarity. One of the
effectors of RNAi is small interfering RNA (siRNA), which is taken
up by a cytoplasmic RNA-induced silencing complex (RISC). The
siRNA programs the endonuclease activity of RISC to cleave
target mRNAs that share sequence identity with it, thereby
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resulting in specific silencing of gene expression [8,9]. The rapid
emergence of RNAi as a potential therapeutic strategy has been
catalysed by the demonstration that it could be induced in
mammalian cells with synthetic siRNA [10] or with short hairpin
RNA (shRNA)-encoding plasmid [11,12] and viral vectors [13–
16]. The shRNAs which are expressed by these vectors in the
nucleus reach the cytoplasm using exportin-5, where they are
processed by Dicer to the corresponding siRNAs [17]. In the
context of antiviral therapy, an advantageous feature of RNAi is its
reliance upon sequence complementarity, which confers the ability
to discriminate the virus from host. This has led to experimental
evaluation of RNAi, both in vitro and in vivo, as an antiviral tool
against a very wide spectrum of viruses [8,18,19] and RNAi-based
antiviral therapies against respiratory syncytial virus and human
immunodeficiency virus are already being tested in the clinic [9].
In contrast, RNAi approaches targeting flaviviruses, particularly
DENVs, are in early stages and focus on two aspects. One is to
develop DENV resistance in mosquitoes, with the objective of
blocking disease transmission [20–22], and the second is to inhibit
DENV replication in mammalian cells using siRNAs targeting the
envelope [23] and the NTRs [15,24].
In this work, we have developed a replication-defective
recombinant adenovirus (rAd) vector, rAdsh-5b, engineered to
express a siRNA targeting a 59NTR sequence element conserved
across multiple DENV serotypes. We show that this vector is able
to suppress efficiently the replication of genomic DENV RNA, the
secretion of NS1 antigen, the release of DENV into the culture
supernatant and the formation of DENV plaques. Interestingly,
our data show that all four serotypes of DENVs are susceptible to
RNAi mediated by the rAdsh-5b vector.
Methods
Cells and viruses
E. coli strains DH5a (for routine cloning) and BJ5183 (for rAd
plasmid creation) were from Invitrogen. The prototypical repre-
sentatives of the four DENV serotypes used in this study were (the
strain and accession numbers are indicated in parantheses):
DENV-1 (Nauru Island, U88535); DENV-2 (New Guinea C,
AF038403), DENV-3 (H87, M93130) and DENV-4 (Dominica,
M14931). The AdV5-transformed human embryonic kidney
(HEK) cell line 293 and the monkey kidney Vero cell line were
from American Type Culture Collection, Virginia, U.S.A. Cell
lines were maintained in Dulbecco’s Modified Eagle medium
(DMEM), supplemented with 10% (v/v) fetal calf serum (FCS), in
a 5% CO2 humidified incubator, at 37uC.
shRNA plasmid construction
Double-stranded 58-mer oligonucleotides encoding shRNAs
targeting each of the sites indicated in Figure 1 were inserted in
place of the 1.9 Kb stuffer sequence of pLKO.1 TRC vector [25],
between the unique Age I and Eco RI sites, under the
transcriptional control of the human U6 promoter as described
in the Addgene plasmid repository website (http://www.addgene.
org/10879/). The panel of constructs generated thus are listed in
the first column of Table 1. The shRNA-encoding inserts in all
constructs were verified by sequence analysis.
Screening of shRNA encoding plasmids
Vero cells, seeded in 96 well plates (at 6000 cells/well), two days
in advance, were transfected with the shRNA plasmids listed in
Table 1 using lipofectamine 2000 (Invitrogen). The lipofection mix
(50 ml/well) contained 0.5 mg plasmid and 0.5 ml lipofectamine
2000 prepared in DME lacking serum and antibiotics as per the
manufacturer’s protocol. An equal volume of DME+10% heat-
treated FCS (DFCS) was added 5 hours later. At 24 hours post
transfection, the media was aspirated and the cells were infected
with each of the four DENV serotypes at a multiplicity of infection
(m.o.i) of 0.1–0.2 (in 50 ml DME+2%DFCS/well), separately. At
2 hours post-infection, each well received 200 ml DME+5%DFCS.
Each transfection/infection was set up in triplicates and the cells
were maintained at 37uC in 10% CO2 throughout. Four days
later, suitably diluted aliquots of the culture supernatants were
analysed for the presence of NS1 antigen using a commercially
available ELISA kit (see below). Experiments were performed
twice independently.
Construction of rAds encoding shRNAs
The human U6 promoter-driven shRNA expression cassette
was retrieved from selected shRNA constructs (sh-5b and sh-scr)
above and inserted into the E1 region of the AdV5 genome of
plasmid pAdEasy-1 by in vivo recombination in E. coli BJ5183 [26].
The resultant recombinant adenoviral plasmid was digested with
Pac I to eliminate plasmid sequences and transfected into HEK
293 cells, to rescue the shRNA-encoding rAd viruses. Three rAds,
one harboring the sh-5b cassette (rAdsh-5b), the next one
harboring the sh-scr cassette (rAdsh-scr), and the last one
harboring an insert-less hU6 cassette (rAd-Empty), were created
for this study. They were verified by PCR and restriction analyses.
All rAds were amplified and titrated on HEK 293 cells as
described before [27]. To detect siRNA in rAd-infected cells, an
RNase protection assay was performed using a commercially
purchased kit (mirVana, Ambion Inc). Briefly, Vero cells were
infected with rAdsh-5b (followed by DENV as described below)
and total RNA prepared at different times post-infection. Total
RNA (,1 mg) was hybridized in solution to ,50,000 cpm [P32]-
radiolabeled sh-5b-specific sense (59-TTAGAGAGCA-
GATCTCTGATGTTTTCCTGTCTC-39) and antisense (59-
CATCAGAGATCTGCTCTCTAACCTGTCTC-39) probes in
20 ml. After 4–5 hours the hybridized products were digested with
the kit-provided RNase A/T1 cocktail (1:100 diluted, 150 ml),
ethanol precipitated and analysed on denaturing (8 M urea) 15%
Author Summary
Dengue is a mosquito-borne viral disease that threatens
nearly half the global population. The symptoms of this
disease, caused by four closely related Dengue viruses,
range from mild fever to potentially fatal haemorrhagic
fever and shock. There is neither a preventive vaccine nor
an effective antiviral therapy against the disease. The
difference between severe and mild disease appears to be
dependent on the viral load. Reducing the virus levels in
the bloodstream through therapeutic intervention may be
associated with favourable prognosis. We investigated the
feasibility of destroying dengue virus genomic RNA using a
phenomenon known as RNA interference, in which the
RNA-cleaving activity of a cellular enzyme complex is
directed to a site in the target RNA, using a short
complementary RNA known as small interfering RNA. We
used adenovirus, a common cold virus, to deliver a small
interfering RNA complementary to a conserved region just
adjacent to the initiator codon in the dengue virus RNA.
We found that this could inhibit viral RNA multiplication,
expression of viral proteins and the secretion of infectious
virus. Importantly, our results showed that the adenovirus
delivered small interfering RNA which could inhibit all four
types of dengue viruses.
A Single shRNA Inhibits All Four Dengue Viruses
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polyacrylamide gels. The radioactive bands were visualized using
the Typhoon 9210 Imager (Amersham Biosciences).
Vero cell infection
Vero cells were seeded in 12-well plates (105 cells/well in 1 ml
DME+10%DFCS) and incubated for 24 hours (37uC, 5% CO2).
These were infected with either rAdsh-5b or rAdsh-scr (diluted in
DME+2%DFCS), each at a m.o.i of 5 (0.25 ml/well). One entire
plate of 12 wells was used for each rAd infection. After 1 hour
adsorption 0.75 ml DME+5%DFCS was added to each well and
the plate returned to the incubator. After 24 hours of exposure to
rAd infection, the cells were subjected to DENV infection. For
this, the culture supernatants from the wells were aspirated and the
monolayers infected with 1000 PFUs of DENV-1, DENV-2,
DENV-3 or DENV-4 in DME+2%DFCS (0.25 ml/well; 3 wells
for each DENV serotype). Two hours later each well received
2.25 ml DME+5%DFCS. Plates were placed in the incubator for 1
week. Mock-infections (neither rAd nor DENV infected) and
DENV infections (no rAd pre-infection) were set up in parallel.
Aliquots (100 ml) of the culture supernatant were withdrawn at
periodic intervals for analysis of DENV NS1 antigen, DENV
genomic RNA and infectious DENV titers. In some experiments,
instead of adding 2.25 ml DME+5%DFCS after DENV exposure,
the wells were overlaid with methylcellulose containing medium to
develop plaques (see below). Experiments were also performed
wherein the order of infections was reversed with DENV infections
first, followed 24 hours later with rAd infections. All infection
experiments were performed twice.
DENV NS1 determination
Culture supernatants collected at various time points, which
were stored frozen at -20uC, were thawed and diluted 1:10 using
DME+2%DFCS. Suitable aliquots of this were used to detect
DENV NS1 antigen using the commercially available Platelia
Dengue NS1 kit (BioRad Inc), as per the manufacturer’s protocol.
This kit uses a pair of NS1-specific monoclonal antibodies to
detect the NS1 antigen produced by all four DENV serotypes.
RNA extraction, strand-specific cDNA synthesis and real
time PCR
DENV RNA from infected culture supernatants (140 ml each)
was extracted using the commercially available QIAmp viral RNA
mini kit (Qiagen) as per the manufacturer’s protocol. Total cellular
RNA from mock-infected and DENV-infected cells was extracted
using the Trizol reagent. The extracted RNA was dissolved in
RNase-free water, quantitated by UV absorbance at 260 nm and
stored frozen at 280uC until use. The RNA samples (250–500 ng
total cellular RNA or 5 ml viral genomic RNA from culture
supernatant) were used to synthesize cDNA using iScript Select
cDNA synthesis kit (BioRad) according to the manufacturer’s
protocol. cDNA corresponding to the plus sense viral RNA
(isolated from culture supernatant) was synthesized using primer
D2. Each sample of cellular RNA was used to generate three
cDNAs corresponding to the sense DENV, antisense DENV and
GAP RNAs using primers D2, D1 and G2 (59-AGGGGTCTA-
CATGGCAACTG-39), respectively. D1 and D2 are consensus
primers common to the genomes of all four DENV serotypes,
described earlier [28]. The cDNAs were used in real time PCR as
follows. Each reaction contained 2.5 ml 106 SYBR green master
mix, 5 ml of suitably diluted cDNA (1:10, 1:50 and 1:100 dilutions
were tested) and 12.5 pmoles of forward and reverse primers and
water in a total volume of 25 ml. For both sense and antisense
DENV cDNAs the primers were D1 and D2, and for the GAP
cDNA, the primers were G1 (59-CGACCACTTTGT-
CAAGCTCA-39) and G2. Real time PCR was carried out using
a BioRad MiniOpticon thermal cycler. A melt curve analysis was
Figure 1. siRNA targets in the DENV NTRs. A ClustalW2 multiple alignment of 59 (A) and 39 (B) NTR sequences of the prototypic representatives
of DENV-1, -2, -3 and -4 (described in Methods) showing the sites conserved in two or more serotypes targeted for RNAi in this study. NTR sequences
that were utilized to design the sense strand of the sh constructs are shown in red fonts. The names of the sh constructs are shown in italics above
the sequences in red fonts. The DENV-4 59NTR seed sequence identical to the sh-5b target site is underlined.
doi:10.1371/journal.pntd.0001735.g001
Table 1. The effect of NTR-specific shRNAs on DENV replicationa.
shRNA Construct Target siteb Conserved in serotypes Cis-acting elementc Percent inhibition
d
D-1 D-2 D-3 D-4
Sh-5a 3–23 1, 2, 3 SLA 33.5 5.1 0 29.1
Sh-5b 79–99 1, 2, 3 59 UAR 51.3 48.2 63.8 70.8
Sh-3a 10,495–10,515 2, 4 nr 0 62.7 0 48.7
Sh-3b 10,579–10,600 1, 2, 4 nr 25.2 71.4 0 86.8
Sh-3c 10,616–10,636 1, 2, 3, 4 39 CS 24.6 78.9 0 76.8
Sh-3d 10,639–10,659 1, 2, 3, 4 39 UAR 16.6 92.6 0 80.3
Sh-3e 10,672–10,692 2, 3 39 SL 19.5 78.7 0 81.1
Sh-3f 10,696–10,716 1, 2, 3 39 SL 22 80.4 0 58.6
aThe production of NS1 antigen, measured using BioRad’s Platelia assay kit, served as a marker of DENV replication; data shown are from one representative screening
experiment.
bThis indicates the location of the 21 nts corresponding to the sense strand of the sh construct-encoded siRNA, on the DENV genome; numbers indicated correspond to
DENV-2 NGC strain (Accession number AF038403).
cSLA: stem-loop A; 59 UAR: 59 upstream AUG region; 39 conserved sequence; 39 UAR: 39 upstream AUG region; 39 SL: 39 stem-loop; nr: not reported.
dThe percent inhibition was calculated with reference to DENV infectivity (in the presence of transfected sh-scr construct), which was taken as 100%. D-1, D-2, D-3 and
D-4 denote DENV-1, DENV-2, DENV-3 and DENV-4, respectively.
doi:10.1371/journal.pntd.0001735.t001
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performed to ensure that amplification was specific. Both sense
and antisense DENV RNAs in total cellular RNA were
normalized to GAP RNA levels.
Plaque assay
Vero cells seeded in 12 well plates (26105 cells/well/1 ml) were
infected 24 hours later with 25 ml DENV-containing culture
supernatants (collected at different time points in the Vero cell
infection experiment above) in a final volume of 250 ml made up
with DME+2%DFCS. Following 2 hours of adsorption, the
inoculum was aspirated off and the monolayers overlaid with
1 ml 0.8% methyl cellulose prepared in 16DME+6%DFCS and
placed in the incubator (37uC; 10% CO2). Four days later viral
plaques were developed using a modification of the immunostain-
ing protocol described earlier [29] with a pan-DENV-specific
monoclonal antibody, 4G2 [30].
Statistical analysis
The statistical significance of differences between rAdsch-scr
and rAdsh-5b treated samples (n = 6) was assessed using two-tailed
Student’s t test. Differences were considered statistically significant
when the probability levels (P) were ,0.05.
Results
A site in the 59 NTR can be used to target all four DENV
serotypes
As the DENV RNA genome contains a single ORF, theoret-
ically one could target any site on it, either within the ORF or
without, to achieve RNAi-mediated silencing effect. Several cis-
acting elements in the NTRs flanking the ORF are important for
successful completion of the viral life cycle (Figure S1). A
59terminal stem-loop structure, SLA, functions as a promoter for
‘minus’ RNA synthesis [31]. Another stem-loop structure at the 39
end (39SL), is essential for RNA replication and virus viability [32].
Further upstream of the 39SL is a conserved sequence (39CS)
involved in long-range interactions with a complementary
sequence at the 59end of the genome, 59CS embedded in the C-
encoding region [3]. Two more sequence elements, one in the
59NTR, an upstream AUG region (59UAR), and its complemen-
tary sequence (39UAR) in the 39NTR also contribute to long-range
interactions between the two ends of the genomic RNA [33].
These long-range interactions mediate circularization of the viral
genome, an event that is critical in both replication and translation
[1]. In principle, targeting these NTR elements to RNAi may help
achieve inhibition of viral replication. Consistent with their
important roles in the viral life cycle, there is a high degree of
conservation of these sequence elements among the DENV
serotypes. We analysed the genomes of representative members
of the four DENV serotypes for 21 nt uninterrupted stretches that
may overlap with the cis-acting sequence elements of the NTRs,
and may serve as putative siRNA target sites. Figure 1 presents a
schematic representation of the putative siRNA target sites chosen
for this study. We identified two sites in the 59NTR (sh-5a and sh-
5b) that overlapped with SLA and 59UAR (Figure S1), respec-
tively, and were completely conserved in DENV-1, -2 and -3. In
the 39 NTR, we identified six potential sites, two (sh-3c and sh-3d),
mapping to the 39CS and 39UAR, were conserved across all 4
DENV serotypes, while the remaining were conserved across
either two or three serotypes. Of these, two sites (sh-3e and sh-3f)
mapped to the 39SL. Using these conserved sequences as putative
siRNA target sites, we next created a panel of shRNA-encoding
plasmid constructs. These shRNA constructs and the sites targeted
by them on the DENV genome, are shown in Table 1 (see also
Figure S1). Each of these constructs was screened against each one
of the four DENV serotypes as explained below.
Vero cells were first transfected with the different shRNA
constructs, including a control construct encoding a scrambled
shRNA insert (sh-scr), and infected 24 hours later with each one of
the four DENVs separately. We then assessed the levels of DENV
replication using NS1 antigen secretion as a surrogate marker.
These data are also shown in Table 1, which summarizes the
percent inhibition of the DENVs by the different shRNA
constructs with reference to DENV infectivity in cells pre-
transfected with sh-scr plasmid taken as 100%. The data indicate
that all shRNAs are successfully processed to their cognate siRNAs
as evidenced by their ability to inhibit replication of one or more
DENV serotypes. However, the observed levels of inhibition
varied widely. Two constructs, sh-3a and sh-3b, behaved
predictably in that they inhibited the DENV serotypes they were
designed to target. The remaining manifested DENV inhibitory
profiles seemingly at odds with their design. For example, sh-3c
and sh-3d, targeting the 39CS and 39UAR elements, respectively,
are conserved in all four DENV serotypes. Yet, DENV-3 was
unaffected by these sh constructs. Similarly, sh-3e and sh-3f
targeting the 39SL are fully conserved in DENV-2 and -3, and
DENV-1, -2 and -3, respectively. But these constructs were most
effective against DENV-2, with no efficacy whatsoever against
DENV-3. The apparent resistance of DENV-3 to RNAi-mediated
inhibition by the panel of shRNAs tested suggests key differences
in the overall secondary structure of the DENV-3 NTRs. The
construct sh-3e showed marginal efficacy against DENV-1.
DENV-4 was susceptible to inhibition by sh-5b, sh-3e and sh-3f,
despite multiple nt mismatches in the sequence stretches in its
NTRs corresponding to these constructs. This may be due to
microRNA (miRNA)-like action, a suggestion consistent with the
view that siRNAs can function as miRNAs when complementarity
with the target site is restricted [9,34]. The notable finding in this
screening experiment was the identification of a single construct,
sh-5b, which inhibited all four DENV serotypes (48–71%).
Interestingly, the target site of sh-5b, which encompasses
59UAR, is fully conserved in DENV serotypes 1–3. Further, a
continuous stretch of 19 internal nts (nt #s 2-18) of the sh-5b
target site, encompassing its seed sequence, is also completely
conserved in DENV-4. We analysed the 59NTRs of the first dozen
DENV isolates from different geographical regions, corresponding
to the four serotypes, listed in the dengue virus portal of Broad
Institute and found the sh-5b target site to be highly conserved
(Figure S2). Based on the results presented above, we decided to
proceed with the sh-5b construct for further work.
Recombinant adenovirus-mediated expression of sh-5b
siRNA
As the introduction of shRNA through a plasmid transfection
approach would be impractical for future use in an in vivo setting,
we created a vector based on AdV5, whose potential to deliver
shRNA successfully has been documented [13,14]. Further, it has
been shown that the endogenous RNAi and interferon pathways
are not significantly affected in cells infected with a recombinant
AdV5 vector encoding sh-RNA [35]. A fragment containing the
human U6 promoter-driven shRNA expression cassette, retrieved
from the sh-5b plasmid, was inserted into the early region 1 (E1) of
AdV5 genome using established strategy [26,27]. A schematic
representation of this rAd vector, rAdsh-5b, is shown in Figure 2A.
In parallel, we also created two additional control rAd vectors,
rAdsh-scr, encoding a scrambled shRNA expression cassette and,
rAdsh-E, containing an empty (insertless) U6 cassette. The
replacement of the E1 region by the ‘sh’ insert in the genomes
A Single shRNA Inhibits All Four Dengue Viruses
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of these rAd viruses was verified by PCR analysis using insert-
specific and E1-specific primers [27]. The results, in Figure 2B,
show that the use of the insert-specific primers generated the
predicted ,1.2 kb amplicons from the genomes of rAdsh-5b and
rAdsh-scr (lanes 2 & 3), but not from those of wild-type (wt) AdV5
and rAdsh-E (lanes 1 & 4). Similarly, the use of E1 primers
produced the expected ,0.47 kb amplicon only when the
template was wt AdV5 DNA (lane 5), but not when it was from
any of the three rAdsh viruses (lanes 6–8). These data were
corroborated by extensive restriction analyses as well (data not
shown).
Vector-borne shRNAs which are transcribed in the nucleus are
similar to pre-microRNAs and like them, mature using the same
Exportin-5/Dicer pathway to siRNAs found in the cytoplasm [17].
To ascertain if the rAdsh-5b vector gives rise to the corresponding
sh-5b siRNA in vivo, we analysed Vero cells infected with this
vector at various times post-infection using an RNase protection
assay. Total RNA from rAdsh-5b infected cells was hybridized to a
Figure 2. Design and characterization of the rAd-sh viruses. (A) The linear genome of the rAd-sh virus constructed for this study. In
constructing the rAd-sh virus, the E1 region (dashed line) is replaced by the sh DNA expression cassette (sh DNA EC), consisting of the U6 promoter
(rightward arrow), the shDNA insert with the sense (s) and antisense (as) arms, of 21 base pairs each, followed by of the U6 terminator (empty box).
The shaded box between the ‘s’ and ‘as’ arms is a 6-base pair loop sequence. The dotted lines flanking the expression cassette represent plasmid
vector sequences. Other elements of the rAd-sh genome include a ,2.7 Kb deletion in the E3 region (DE3), the left (L) and right (R) inverted terminal
repeats, and the packaging signal (y). The nt sequences of the ‘s’ strands of the sh-5b and sh-scr constructs are shown below. (B) PCR analysis of wild
type AdV5 (lanes 1 & 5), rAdsh-E (lanes 4 & 8), rAdsh-5b (lanes 2 & 6) and rAdsh-scr (lanes 3 & 7) using insert-specific (lanes 1–4) and AdV5 E1-specific
(lanes 5–8) primers. DNA size markers (sizes in kb shown to the left) were analyzed in lanes ‘M’. The arrows to the right denote the positions of the
predicted insert-specific (upper) and AdV5 E1 region-specific (lower) amplicons. (C) RNase protection assay to detect anti-sense strand of sh-5b siRNA.
A radiolabeled sense probe was digested with RNases A and T1, either before (lanes 2 & 5) or after hybridization with total RNA isolated from rAdsh-
5b-infected Vero cells, harvested on either day 3 (lane 3) or day 8 (lane 6) post-infection. Protected fragments (lower arrow) were analysed on 8 M
urea gel and visualized using a phosphoimager. The un-hybridized probe (upper arrow) without any RNase treatment was analysed in parallel (lanes 1
& 4). It is to be noted that in lanes 3 and 6, the cells used for total RNA preparation were challenged with DENV-2 and DENV-4, respectively, at
24 hours post rAdsh-5b infection.
doi:10.1371/journal.pntd.0001735.g002
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33 nt long radiolabeled sense probe, subjected to RNase treatment
and analysed on denaturing gels to detect the 21 nt protected
antisense strand of sh-5b siRNA. Results from a typical
experiment performed with total RNA obtained at two different
time points are shown in Figure 2C. The sense probe was
specifically protected in the presence (lanes 3 & 6), but not in the
absence (lanes 2 & 5) of total RNA derived from cells that had
been exposed to rAdsh-5b infection, indicating the presence of the
complementary antisense strand of sh-5b siRNA. Interestingly, we
could detect the antisense strand as late as eight days following
rAdsh-5b infection. This was corroborated by detection of the
sense strand of this siRNA using a complementary antisense probe
(data not shown). These data confirmed the successful intracellular
delivery of siRNA by the rAd vector.
The rAd vector per se does not affect replication of any of
the DENV serotypes
Before analysing the effects of rAdsh-5b mediated RNAi on
DENV replication, we sought to ascertain that the rAd vector does
not in itself interfere with DENV replication. In order to do this,
we compared the DENV genomic RNA levels in cells in the
presence and absence of rAdsh-scr control vector, encoding an
irrelevant scrambled shRNA, referred to above. In this experi-
ment, Vero cells were first infected with rAdsh-scr, followed
24 hours later with DENV-1, DENV-2, DENV-3 or DENV-4.
Viral sense RNA isolated from the culture supernatant at different
times post-DENV infection was analyzed by real time RNA PCR.
We examined the levels of both sense and antisense viral RNAs in
total cellular RNA prepared at different times post-DENV
infection (Figure S3). We found that both kinds of RNA samples,
obtained either from cells infected only with DENV or from those
pre-infected with rAdsh-scr prior to DENV infection, manifested
virtually similar real time amplification profiles, for all four DENV
serotypes (p.0.05). Further, this was true regardless of whether we
examined viral RNA in culture supernatant or total cellular RNA,
on day 2 or day 7 post-DENV infection. These data demonstrated
that neither the sh-scr RNA construct nor the rAd vector used to
deliver it into cells had any discernible effect on DENV
replication. Thus, the rAdsh-scr vector could serve as a good
control to evaluate the effects, if any, induced by the rAdsh-5b
vector on DENV replication.
sh-5b siRNA delivered using rAd vector is a powerful
inhibitor of DENV-1, -2, -3 and -4
Next, using rAdsh-scr as the reference, we evaluated the effect of
rAdsh-5b on prototypic representatives of all four DENV serotypes
in a plaque assay format. In this experiment, Vero cells were first
infected with either rAdsh-scr (control) or rAdsh-5b (test) and then
challenged 24 hours later with each of the DENV serotypes
separately. Immediately following DENV infection, the monolay-
ers were overlaid with methyl cellulose and incubated to allow
plaque formation. The results are shown in Figure 3. This
experiment shows that rAdsh-scr pre-infection had no discernible
effect on the number of DENV plaques formed in all four
serotypes (compare rows A & B), In striking contrast, pre-
treatment with rAdsh-5b resulted in a remarkable level of
suppression of plaque formation by all four DENV serotypes
(row C). This observation which is consistent with the behaviour of
the plasmid-borne sh-5b construct in the screening experiment
described above demonstrates the feasibility of achieving inhibi-
tion of all four DENV serotypes using a rAd vector to deliver sh-5b
siRNA into cells. However, as plaque reduction assays are usually
performed in 24-well plates with limited amount of DENV
(50 PFUs/well), it is likely that this may be responsible for the near
total inhibition of the DENVs in this experiment.
Significant DENV inhibition can be achieved by rAdsh-5b
at high DENV dosage
We next sought to address if the rAdsh-5b would be effective in
inhibiting DENVs if the challenge dose were to be significantly
increased. To this end, we set up an experiment similar to the one
above with the following two differences. One, we increased the
dose of challenge DENV 20-fold (1000 PFUs/well); and two,
instead of methyl cellulose overlay, liquid growth medium was
added to cells followed by sampling of cultures periodically for 1
week post-DENV infection for analysis of genomic RNA levels,
NS1 antigen secretion, and infectious virus production.
The results of a comparison based on real time RNA PCR assay
of the relative DENV genomic RNA levels (normalized to GAP
RNA levels) in DENV-infected cells between the rAdsh-scr pre-
treated (control) and rAdsh-5b-pre-treated (test) samples are
summarized in Figure 4. In this experiment the DENV RNA
level in the test sample has been expressed relative to that in the
corresponding control sample, which was arbitrarily set at 1.0. It is
immediately apparent that test RNA levels are a fraction of the
control RNA levels across the board, showing that rAdsh-5b
exerted a uniformly inhibitory effect on all DENV serotypes. An
analysis of sense viral RNA levels at day 2 post DENV infection is
presented in panel B. DENV-1 and -2 sense RNA levels
manifested very high inhibition (.80%) compared to their
corresponding controls, while DENV-3 and DENV-4 sense
RNA levels suffered relatively lesser degree of reduction (,50–
60%). By day 7, sense RNA was virtually indiscernible for DENV-
1 and -4, and .70% reduced in DENV-3, with respect to their
cognate controls. DENV-2 sense RNA levels did not manifest
further reduction beyond ,80% seen at day 2 post-DENV
infection (panel D). The observed inhibition in the levels of sense
viral RNA seen for all four DENV serotypes was mirrored in the
antisense RNA levels as well (panels A and C), with the inhibition
being relatively greater than that observed for sense RNA.
Figure 3. The effect of rAd mediated sh RNA expression on
DENV plaque formation. Vero cells in 12-well plates, were
sequentially infected with rAdsh-5b (row C) or rAdsh-scr (row B), and
24 hours later, with DENV-1 (column 1), DENV-2 (column 2), DENV-3
(column 3) and DENV-4 (column 4). In parallel control experiments, the
rAd infection was omitted and only DENV infections performed (row A).
Cells were overlaid with methyl cellulose and stained four days later
with a pan-DENV-specific monoclonal antibody to visualize the viral
plaques. One experiment of two performed is shown.
doi:10.1371/journal.pntd.0001735.g003
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Further, the reduction in antisense RNA levels was more
pronounced on day 7 (panel C) compared to that on day 2 (panel
A), as seen for sense RNA levels. The greater susceptibility of
antisense DENV RNA to inhibition, compared to its sense
counterpart, may be a reflection of the lower copy number of the
former [3]. In all instances, the reduction in genomic RNA of the
test samples, compared to the cognate reference samples, was
significant (P,0.05).
During the course of the experiment described above, we also
withdrew aliquots of the culture supernatant at regular intervals and
determined the levels of NS1 antigen using a commercially available
ELISA kit. These data are depicted in Figure 5. In the control
samples, NS1 secretion was discernible after day 3 post-DENV
infection, which peaked about 2–3 days later and plateaued
thereafter. While the NS1 secretion profiles of DENV-1, -2 and -3
were more or less comparable to each other, the NS1 secretion
profile of DENV-4, though qualitatively similar, was quantitatively
lower in the controls. This is presumably inherent to DENV-4 or a
reflection of the lowered sensitivity of the kit in picking up DENV-4
NS1. The kinetics of NS1 secretion by the DENVs in the absence of
prior rAdsh-scr infection was essentially similar (data not shown).
Remarkably, we found that NS1 antigen secretion was almost
completely inhibited in the test samples compared to their respective
controls, for all four DENV serotypes tested (P,0.05).
The suppression in viral antigen secretion would suggest that
virus production would also be reduced. This was borne out by an
examination of the virus titers in the culture supernatant. Figure 6
depicts virus titers, measured using a standard plaque assay, in the
same aliquots used for NS1 determination described above. The
virus titers in the case of DENV-1, -2 and -3 controls rose
gradually, peaking at day 5 post-DENV infection. The DENV-4
control experiment manifested somewhat delayed kinetics, peaking
at day 7, a trend mirroring the NS1 secretion profile described
above. In comparison, the rate of virus secretion into medium in
the test experiments was noticeably, but not completely, ablated.
This contrasts with the observed NS1 secretion profiles (Figure 5),
which manifested near total ablation in response to rAdsh-5b pre-
treatment. Observed DENV titers in the test groups manifested
70–90% reduction compared to their corresponding controls
(P,0.05).
rAdsh-5b is effective against on-going DENV infection
In the experiments described so far, the sh-5b shRNA was
already introduced into the cells before infecting them with
DENV. To get a more accurate assessment of the possible
therapeutic potential of this approach, we infected cells first with
DENV and then introduced the shRNA via the rAd vector. In the
first such experiment, which was a plaque reduction assay similar
to the one in Figure 3, cells were infected first with DENV-2, and
24 hours later with either rAdsh-scr or rAdsh-5b, and immediately
overlaid with methyl cellulose-containing medium. Two doses of
each rAd virus were tested in this experiment, one corresponding
to the dose in the earlier set of experiments (m.o.i = 5) and the
other which was twice as much (m.o.i = 10). Typical results are
presented in Figure 7A. It is evident that at both doses of rAdsh-5b
tested, a noticeable reduction in plaque counts was discernible.
Next, we repeated this experiment, as before, with a higher dose of
DENV-2 (1000 PFU/well), followed 24 hours later with rAdsh-scr
or rAdsh-5b, at two different doses as above. Infected cells were
fed with liquid medium which was sampled at 48 hour intervals
over a one-week period for analysis of NS1 antigen levels and
DENV-2 titers. These data are summarized in Figures 7B and 7C,
respectively. NS1 antigen secretion which was initially inhibited by
rAdsh-5b, at the lower dose, reached control levels by day 7 post-
infection. However, this could be counteracted at higher rAdsh-5b
dosage (Figure 7B). In contrast, the lower dose of rAdsh-5b was
nearly as effective as the higher dose in inhibiting the production
of infectious DENV-2 (Figure 7C). The data in Figures 7B and 7C,
taken together, would suggest that at the lower dose of rAdsh-5b
tested, continued translation of the residual viral genomic RNA is
responsible for the observed rise in NS1 levels (at day 7). This is
consistent with the observation that increasing the rAdsh-5b
dosage brings down the NS1 levels, presumably through increased
degradation of the DENV-2 genomic RNA.
Discussion
One approach to deploying RNAi against multiple DENV
serotypes would be to target its action to conserved sequences on
the genomes of the four DENV serotypes [15,24]. In this report,
we have explored the feasibility of targeting conserved cis-acting
Figure 4. The effect of rAd-mediated shRNA expression on DENV RNA accumulation. Vero cells were pre-infected either with rAdsh-5b
(red bars) or rAdsh-scr (green bars) followed 24 hours later by infection with DENV-1, DENV-2, DENV-3 and DENV-4. Total RNA was isolated on days 2
(panels A and B) and 7 (panels C and D) post-DENV infection and analyzed for DENV ’minus’ (panels A and C) and ‘plus’ (panels B and d D) sense viral
genomic RNAs by strand-specific real time PCR analyses. DENV RNA was normalized to GAP RNA in each sample analyzed. The data depict DENV RNA
levels in rAdsh-5b treated cells relative to those in the corresponding rAdsh-scr treated cells. Each experiment was carried out in triplicate wells and
the entire experiment repeated twice.
doi:10.1371/journal.pntd.0001735.g004
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elements in the NTRs to achieve RNAi-mediated inhibition of
multiple DENV serotypes. We tested each of these putative sites,
on each DENV serotype, using plasmid-delivered shRNAs, by
assaying the levels of NS1, a viral antigen used as a marker of virus
replication [36,37]. An earlier study which reported that a shRNA
targeting the 39 CS region can inhibit DENV-2 infection in Vero
cells and DCs implied that it may be a pan-DENV inhibitor [15].
However, we found that the sh-3c construct (targeting 39 CS) was
active on DENV-2 and DENV-4, but not on DENV-1 and
DENV-3. This, taken in conjunction with our results (Table 1)
lead to the suggestion that an interplay of other factors, such as
structural constraints and the degree of accessibility of the
conserved target sequence presumably determine RNAi suscepti-
bility. Our work which showed that sequence complementarity
alone does not ensure susceptibility of all four DENV serotypes to
RNAi, helped experimentally identify one construct, sh-5b, as a
pan-DENV inhibitor. Interestingly, 21/21 sh-5b target site nts are
fully conserved in DENVs 1–3, whereas in DENV-4, 19/21 nts
are conserved. Significantly, all four DENV serotypes have an
intact 59UAR element, which is presumably accessible to the
RNAi machinery.
Next, we developed an AdV5-based viral vector, rAdsh-5b, for
its efficient intracellular delivery, after ensuring that the AdV5
vector per se did not affect DENV replication. We showed that
AdV5 vector-delivered sh-5b shRNA matures into its cognate
siRNA, which persisted for several days in rAdsh-5b-infected Vero
cells. We analysed the effect of rAd-mediated delivery of sh-5b
siRNA on the replication of all four DENV serotypes in terms of
antigen synthesis, viral RNA synthesis and infectious virus
production. In these experiments, cells pre-exposed to rAdsh-5b
were challenged with different DENVs. While DENV NS1
antigen levels manifested near total suppression in rAdsh-5b pre-
treated cells, viral RNA accumulation and infectious virus
production were significantly, but not completely, abolished
(Figures 3, 4, 5, 6). Importantly, we did not observe any
discernible change in the levels of GAP RNA levels in response
Figure 5. The effect of rAd-mediated shRNA expression on DENV NS1 antigen secretion. Vero cells were pre-infected either with rAdsh-5b
(red curves) or rAdsh-scr (green curves) followed 24 hours later by infection with DENV-1 (A), DENV-2 (B), DENV-3 (C) and DENV-4 (D). Culture
supernatants were drawn at daily intervals up to 7 days post DENV infection and analyzed for the presence of NS1 antigen using BioRad’s Platelia
Dengue NS1ELISA kit. The data represent plots of NS1 ELISA absorbance as a function of time after DENV infection. Data shown are mean values
(n = 6). The vertical bars represent standard deviation, SD.
doi:10.1371/journal.pntd.0001735.g005
Figure 6. The effect of rAd mediated shRNA expression on DENV secretion. Vero cells were pre-infected either with rAdsh-5b (red curves) or
rAdsh-scr (green curves) followed 24 hours later by infection with DENV-1 (A), DENV-2 (B), DENV-3 (C) and DENV-4 (D). Culture supernatants were
drawn at daily intervals up to 7 days post DENV infection and analyzed for the presence infectious DENV using a standard plaque assay. Data shown
are mean values (n = 6). The vertical bars represent SD.
doi:10.1371/journal.pntd.0001735.g006
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to rAdsh-5b treatment suggesting that the likelihood of possible
off-target effects may be low. Interestingly, we observed that a
DENV-2 infection which was already underway for 24 hours was
also susceptible to RNAi induced by rAdsh-5b in a dose-
dependent manner (Figure 7). Earlier studies have not examined
this aspect [15,24], and this work demonstrates for the first time
that RNAi, mediated by an AdV5 vector, may have potential
utility as an antiviral tool in the context of on-going DENV
infection. A similar AdV5 vector-based shRNA approach has
shown promise in attenuating pre-established HBV infection [14].
However, our results raise several issues as discussed below.
A recent study which screened a panel of DENV-specific
siRNAs in Huh7 cells using plaque assays and Western blotting
assays, found that one of them targeting the 59CS element
functioned as a pan-DENV inhibitor [24]. Though the present
study did not include 59 CS as a target for RNAi, the observation
that the sh-3c construct (which targeted the complement of 59CS
in the 39 NTR), inhibited DENV-2 and DENV-4, may be
regarded to be partly consistent with the earlier report [24].
However, two additional siRNAs in the earlier study, DC-1 and
DC-2, whose target sites happened to overlap considerably with
the sh-5a and sh-5b sites, respectively, yielded results that were
different from ours. Specifically, the DC-2 siRNA which shared 18
of the 21 nts comprising the sh-5b target site failed to inhibit any
of the DENVs. The reason for the apparent differences between
the previous and current studies is unclear. A definitive
comparison is difficult given the differences in cell types,
methodology, subtle differences between the siRNAs (especially
at the 39ends) and the mode of delivery in the two studies.
Regardless of whether rAdsh-5b was used before or after onset
of DENV infection we did not achieve complete inhibition of virus
replication. This is an inherent attribute of RNAi-mediated
silencing and could be perceived as a limitation of this approach
in a therapeutic context, wherein total inhibition is necessary. One
may anticipate achieving higher levels of inhibition by targeting
additional sites on the DENV genomes (see below). Also,
increasing the dose of the shRNA-encoding vector may contribute
to greater efficiency of silencing. However, in the case of dengue
the difference between mild and potentially fatal disease is the high
viral load in the latter [5,6]. Based on this it may be speculated
that a reduction in viral load may be adequate to attenuate disease
severity.
We have tested one prototypic representative of each of the four
DENV serotypes. Would multiple isolates within each of the four
DENV serotypes manifest susceptibility to sh-5b siRNA? An
analysis of the 59NTR sequences of several isolates of DENV-2,
and -3 serotypes listed in the Dengue Virus portal of the Broad
Institute revealed absolute conservation of the sh-5b target site. In
the case of DENV-1, Vietnamese isolates differed in one nt, but
several Cambodian and Thai DENV-1 isolates listed in this
database, once again displayed 100% conservation of the sh-5b
target site (not shown). In the case of DENV-4, the isolates
displayed 90% identity with sh-5b target sequence, with all
possessing an intact 59 UAR element, similar to the prototypic
DENV-4 strain examined in this study. By and large, the sh-5b
target sequence is highly conserved. The possibility of the
inherently error-prone RNA replication machinery facilitating
escape from RNA may be counteracted to a certain extent by the
high degree of conservation of the sh-5b target site. However, our
observation of residual viral RNA and infectious viral titers,
especially at high DENV challenge doses, suggests that it would be
desirable to develop vectors that could encode additional shRNAs,
collectively targeting each of the DENV serotypes, preferably at
more than one or two sites.
How appropriate is it to use AdV5 as a shRNA delivery vector,
given its potential to interact with the host antiviral response
pathways? AdV5-encoded virus-associated RNAs (VA-RNAs)
have the potential to interact with RISC and interfere with the
Figure 7. The effect of rAd mediated shRNA expression on on-going DENV infection. (A) Vero cells in 12-well plates were sequentially
infected with DENV-2 (,25 PFU/well) and 24 hours later, with rAdsh-scr or rAdsh-5b, each at a m.o.i of 5 (top row) or 10 (bottom row). Cells were
overlaid with methyl cellulose and plaques visualized as explained in Figure 3 legend. Two wells, of four assayed for each sequential infection
experiment, are shown. (B) Vero cells in 24-well plates were sequentially infected with DENV-2 (1000 PFUs/well), followed 24 hours later with rAdsh-
5b (red curves) or rAdsh-scr (green curve), each at m.o.i. of 5 (solid curve) or 10 (dashed curve). Culture supernatants were drawn at 48 hour intervals
up to 7 days post DENV infection and analyzed for the presence of NS1 antigen using BioRad’s Platelia Dengue NS1ELISA kit. The data represent plots
of NS1 ELISA absorbance as a function of time after DENV infection. Data shown are mean values (n = 4). The vertical bars represent SD. (C) Culture
supernatants in (B) were analyzed for the presence infectious DENV using a standard plaque assay. Data shown are mean values (n = 4). The vertical
bars represent SD.
doi:10.1371/journal.pntd.0001735.g007
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RNAi pathway [38,39]. In this regard, it is relevant to note that
our vectors lack E1 genes, a defect associated with extremely low
levels of VA-RNA expression [38]. Further, experimental analysis
of cells infected with a rAdsh-RNA vector has not revealed any
significant effect on either the RNAi or the interferon response
pathways [35]. This is consistent with our observation that the rAd
vector per se does not affect DENV replication and emphasizes the
utility of AdV5 as a suitable vector for mediating shRNAs into the
cell. Another issue concerning the suitability of AdV5 vector is that
its efficacy may be compromised in a majority of the human
population which is seropositive for AdV5 [40]. However, it has
been shown that AdV5 complexed to specific antibodies can be
taken up into macrophages and dendritic cells through Fc
receptors [40,41]. As these are the very cell types wherein DENV
replicates in vivo [42,43], an intriguing possibility is that the
existence of anti-AdV5 antibodies may in fact facilitate the
delivery of the shRNAs into these cells.
In conclusion, the observation of suppression of all four DENV
serotypes based on multiple parameters such as viral antigen
secretion, genomic RNA levels and infectious virus production,
which are mutually corroborative demonstrate the utility of rAd-
mediated delivery of shRNAs as an effective tool to abrogate
DENV replication. However, additional conserved and accessible
sites need to be targeted to counter viral escape. We note that
these results obtained using a tissue culture model need to be
verified in a small animal model such as AG129. A recent study
has achieved DENV inhibition in this model using chemically
synthesized siRNA [24]. As the difference between severe and
mild disease appears to be dependent on the viral load, early
diagnosis can facilitate timely therapeutic RNAi-based interven-
tion to change the course of disease from DHF to DF by bringing
down the high viremia.
Supporting Information
Figure S1 Cis-acting DENV NTR elements targeted by
the sh constructs. The DNA sequences shown correspond to 59
(A) and 39 (B) NTRs of DENV-2 New Guinea C strain (Accession
no. AF038403). The cis-acting sequence elements, SLA, 59 UAR,
39 CS and 39 UAR are underlined. The 39 SL element is double-
underlined to delineate it from the 39 UAR right next to it. Nts in
red font denote the sequences targeted for RNAi, with the names
of the corresponding sh constructs shown above in italics.
(TIF)
Figure S2 Conservation of the sh-5b/59 UAR sequences
within and across the four DENV serotypes. The figure
displays ORF-proximal region of the 59 NTRs of the first dozen
isolates of each DENV serotype listed in the Broad Institute
dengue virus portal (http://www.broadinstitute.org/annotation/
viral/Dengue/SequenceSearch.html). Corresponding DNA se-
quences were retrieved from NCBI. The accession numbers of
the isolates are shown on the left. The sh-5b target sequence is
highlighted in yellow. The single nt mismatch in many of the
DENV-1 isolates examined is highlighted in green. Shown on top
is the sequence of the sh-5b target site, with the 59 UAR sequence
within it shown by the underline.
(TIF)
Figure S3 Real time PCR analysis of DENV RNA levels
in Vero cells pre-infected with rAdsh-scr. Vero cells were
either mock-pre-infected (blue curves) or pre-infected with rAdsh-
scr (green curves) for 24 hours followed by infection with DENV-1
(A), DENV-2 (B), DENV-3 (C) and DENV-4 (D). Total cellular
RNA was isolated on day 7 post-DENV infection and analyzed for
DENV ‘plus’ sense genomic RNA by real time PCR. The
horizontal dashed line indicates the baseline used to determine Ct
values.
(TIF)
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